The Multiple Myeloma and Amyloidosis program provides a valuable resource to patients with these conditions. We offer a comprehensive array of services and treatment options based on the specific challenges of each patient's disease characteristics and stage. Through our various clinical trials, patients with multiple myeloma can access leading-edge, novel therapeutics. The clinical trials are complemented by the program’s basic and translational research in several promising areas, including anti-angiogenesis, vaccines, anti-virus treatments, gene therapy and third-generation bisphosphonates.
Multiple Myeloma Cancer
Jeanette Tersigni, 70, went into remission from multiple myeloma. But what her family couldn't see was the the isolation and anxiety she felt inside. But through the Cancer Survivorship and Rehabilitation program, she was able to find strength for more comprehensive healing, letting go of the darkness that cancer had put over her life...Read Full Story
Amyloidosis can affect the heart, kidneys, liver, nervous system, and intestines. For patients with amyloidosis that affects the heart, the condition is rare, affecting fewer than 4,000 people in the United States each year. Support for these patients is crucial to improving quality of life...Read More